meglumine antimoniate (Glucantime in France, Glucantim in Italy)
Jump to navigation
Jump to search
Indications
Dosage
- parenteral (intravenous[2][3], intramuscular[1]
- 20 mg/kg/day for 20 days[5]
Adverse effects
- fever, rash, arthralgia, abdominal pain
- skin eruption
- pruritus and erythema in the site of injection
- urticaria
- pancreatic toxicity: hyperamylasemia, increased serum lipase
- increased serum transaminases
- pancytopenia
- renal failure, hepatic failure, death
Notes
- lower efficacy in treating cutaneous leishmaniasis in children than adults[5]
More general terms
References
- ↑ 1.0 1.1 Wikipedia: Meglumine antimoniate http://en.wikipedia.org/wiki/Meglumine_antimoniate
- ↑ 2.0 2.1 Mayo Clinic Meglumine Antimoniate (Intravenous Route, Injection Route). http://www.mayoclinic.org/drugs-supplements/meglumine-antimoniate-intravenous-route-injection-route/description/drg-20064644
- ↑ 3.0 3.1 Ezzine Sebai N1, Mrabet N, Khaled A et al [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases]. Tunis Med. 2010 Jan;88(1):9-11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20415206
- ↑ Roberts WL et al Characterization of the Antimonial Antileishmanial Agent Meglumine Antimonate (Glucantime). Antimicrob Agents Chemother. May 1998; 42(5): 1076-1082. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/9593130 <Internet> http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105748/
- ↑ 5.0 5.1 5.2 Layegh P, Rahsepar S, Rahsepar AA. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults. Am J Trop Med Hyg. 2011 Apr;84(4):539-42. doi:http://dx.doi.org/ 10.4269/ajtmh.2011.10-0002. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21460006